| ACCC | Association for Community Cancer Centers |
| ALL | Acute lymphoblastic leukemia |
| ASTCT | American Society for Transplantation and Cellular Therapy |
| BCMA | B-cell maturation antigen |
| B-ALL | B-cell acute lymphoblastic leukemia |
| CAR T | Chimeric antigen receptor T cell |
| CI | Confidence interval |
| CIBMTR | Center for International Blood and Marrow Transplant Research |
| CIDR | Cellular Immunotherapy Data Resource |
| CLL/SLL | Chronic lymphocytic leukemia/small lymphocytic lymphoma |
| CRS | Cytokine release syndrome |
| DEPICT | Diverse and Equitable Participation in Clinical Trials |
| FACT | Foundation for Accreditation of Cellular Therapies |
| FDA | Food and Drug Administration |
| FL | Follicular lymphoma |
| ICANS | Immune effector cell-associated neurotoxicity syndrome |
| LBCL | Large B-cell lymphoma |
| MCL | Mantle cell lymphoma |
| MM | Multiple Myeloma |
| NIH | National Institutes of Health |
| OR | Odds ratio |
| OS | Overall Survival |
| PFS | Progression-free survival |
| REMS | Risk Evaluation and Mitigation Strategies |
| RPM | Remote patient monitoring |
| SEER | Surveillance, Epidemiology, and End Results Program. |
| VTE | Venous thromboembolism |